Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>Videos>This Video


Advance drug discovery by improving dose-response curve set-up

Tecan Group Ltd.

Richard Marcellus, Molecular Biologist, Ontario Institute for Cancer Research Save time and reduce waste while improving data quality for small molecule dose-response curves Titration of small molecules in DMSO is a ubiquitous part of the drug discovery workflow. Traditional methods require serial dilution which can be wasteful in terms of tips, intermediate plates and compounds. This process is also time consuming, and reproducibility from researcher to researcher can be a challenge. Traditionally, laboratories have had to accept the potential for carry-over and accumulated pipetting errors, as well as the high labor costs associated with this task. In addition, many laboratories are not performing scientifically optimal titrations, due to equipment or time restrictions. For example, in vitro drug-drug interaction experiments are often desired, but are too complicated to perform routinely. Low- and medium-throughput laboratories, such as therapeutic or lead optimization departments, cannot always justify the purchase of large automation equipment. Not only can the cost of these systems be prohibitive, they can also impose undesirable limits on assay set-up, and often require specialist knowledge to maintain and program. These laboratories need an affordable solution that meets their demands for flexibility, speed and reliability. Join our webinar as we examine the potential for change in dose-response curve set-up for small molecules in DMSO, leading to time savings and dose and plate layout flexibility for drug discovery biologists. Key Learning Objectives • Explore methods to save time and reduce labor costs when setting up dose-response curves • Save precious compounds and eliminate waste of consumables and reagents • Quickly set up drug-drug interaction experiments, along with other complex plate layouts • Improve data quality in dose-response curves and decrease the number of bioassay wells required Richard C. Marcellus, Ph.D. Biochemist - Ontario Institute for Cancer Research, Toronto, Canada Richard has spent over a decade working in cancer drug discovery and has broad experience ranging from target identification, to assay development and HTS, SPR-based protein-drug interaction analysis, and drug target validation. He currently works in the Medicinal Chemistry Group at the OICR, a translational research institute. Richard runs in vitro assays in support of SAR programs, and has embarked upon a targeted screening program in patient-derived primary cancer cells. In this study drug sensitivity is being combined with RNAi and deep sequencing to identify promising anti-cancer targets.

Request more information
Company product page

Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos